A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer is a research paper published in European Journal of Cancer (2020). On theSindex it has a DataRank of 0.435. It has been cited 7 times, with 5 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.124
From 5 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
NIGMS NIH HHS
Grant: U54 GM104942
NCI NIH HHS
Grant: P30 CA016672
Prostate Cancer Foundation
Janssen Pharmaceuticals
Pfizer
Bristol-Myers Squibb
National Institutes of Health
FWCI
0.66
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals